TABLE 3

Responses to selected questionnaire items in relation to national tuberculosis (TB) incidence

Questionnaire itemLow TB incidence (<10 per 100 000)Medium/high TB incidence (≥10 per 100 000)
Countries2110
National TB control plan or strategy9 (42.9)8 (80.0)
Clearly defined organisational structure13 (61.9)10 (100.0)
Central coordination18 (85.7)10 (100.0)
Specific funding allocated to TB control2 (28.6)3 (30.0)
High-priority actions
 Training and developing a specialist TB workforce10 (47.6)5 (50.0)
 Introducing and implementing new tools for TB control8 (38.1)6 (60.0)
 External quality assurance for laboratory services7 (33.3)5 (50.0)
 Implementing electronic TB case registries12 (57.1)6 (60.0)
 Staffing and expertise for national TB surveillance9 (42.9)3 (30.0)
 Establishing or managing local TB control boards4 (19.1)1 (10.0)
 Publishing and disseminating clinical guidelines6 (30.0)5 (50.0)
 Raising awareness of TB at community/primary care level8 (38.1)5 (50.0)
 Reaching vulnerable population groups17 (81.0)7 (70.0)
 TB control in prisons8 (38.1)6 (60.0)
 Latent TB infection screening in high-risk population groups11 (52.4)4 (40.0)
 Screening for active TB in high-risk population groups13 (61.9)6 (60.0)
 Ensuring continuity of TB drug supply8 (38.1)6 (60.0)
 Screening for active TB in migrants from high-incidence countries14 (66.7)3 (30.0)
 Contact tracing and outbreak investigation13 (61.9)5 (50.0)
 BCG vaccination2 (9.5)2 (20.0)
 MDR-TB10 (47.6)8 (80.0)
 HIV/TB7 (35.0)7 (70.0)
Barriers to TB control and prevention
 Recipients of care barriers (range 0–6)3 (1–4)3 (2–4)
 Providers of care barriers (range 0–5)2 (1–3)1.5 (1–3)
 Social and political constraints (range 0–6)2 (0–3)1 (0–2)
 Health system constraints (range 0–27)5 (2–7)6.5 (2–10)

Data are presented as n, n (%) or median (interquartile range). BCG: bacille Calmette–Guérin; MDR: multidrug-resistant.